Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04234633
Other study ID # A44
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 2020
Est. completion date March 2022

Study information

Verified date January 2020
Source Assiut University
Contact Ahmed Aeltaih, MBBch
Phone +201159486891
Email a.safwat.4842@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators aim to compare the clinical characteristics and outcomes of SLE between male and female Egyptian patients at Assuit University Hospital.


Description:

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology and is characterized by a multifaceted clinical presentation and disease course. Female predominance is a well-known characteristic of SLE, particularly during the reproductive years. Sex differences are another peculiarity of SLE with respect to clinical manifestations and outcomes. Previous studies have recognized male patients with lupus as a distinct minority; such patients often exhibit a poorer prognosis, especially involving the renal, cardiovascular, and neurologic systems. Higher mortality rates in male than in female patients with SLE have also been reported. Andrade et al reported that multiple conditions (for example, severe skin lesions, serositis, thrombotic events, and seizures) are more frequent in males than females.

Lu et al investigated the frequency of renal failure and end-stage renal disease among both genders and found out that these conditions were more prevalent among males. Another study shows no difference in complications and prognosis between both genders.

The results of these previous studies may not be applicable to all ethnic groups. For example, Mok et al studied the males in the local Chinese population had different disease features in term of clinical features at diagnosis, rate, and severity of relapse, organ damage and cumulative damage score. They found through a retrospective review that at the time of diagnosis, there was a trend, however not statistically significant, that males had less Raynaud's, alopecia, arthritis, anti-Ro antibody, but more thrombocytopenia and discoid lesions. Also, a significantly higher number of males had impaired renal functions.

There are few studies that have assessed the differences between male and female Egyptian patients with SLE according to the presentation, complication, prognosis, and mortality. One of these studies shows a more aggressive disease detected in male patients. This was evident by a higher prevalence of nephritis, fever, cutaneous vasculitis in male patients. on the other hand, alopecia and arthritis were significantly higher in females.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date March 2022
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

• Any SLE patients between 18and 40 years old will be eligible to be included in our study.

Exclusion Criteria:

- Patients below the age of 18 or above 40.

- Any other autoimmune disease.

- Cardiovascular, neurological, renal complications due to other co-morbidity such as DM and HTN.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (3)

El Hadidi KT, Medhat BM, Abdel Baki NM, Abdel Kafy H, Abdelrahaman W, Yousri AY, Attia DH, Eissa M, El Dessouki D, Elgazzar I, Elgengehy FT, El Ghobashy N, El Hadary H, El Mardenly G, El Naggar H, El Nahas AM, El Refai RM, El Rwiny HA, Elsman RM, Galal M, — View Citation

Mok CC, Lau CS, Chan TM, Wong RW. Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus. 1999;8(3):188-96. — View Citation

Soto ME, Vallejo M, Guillén F, Simón JA, Arena E, Reyes PA. Gender impact in systemic lupus erythematosus. Clin Exp Rheumatol. 2004 Nov-Dec;22(6):713-21. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Presentation, complication, and mortality among males and female patients with SLE Using percentages, we will track the number of patients that develop certain clinical conditions (such as arthritis, malar rash, .... ), complications (such as nephritis), and mortality rates. These numbers and percentages will be used to compare males with females (incidence rates for each event will be calculated). 2 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05479071 - Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
Completed NCT02240888 - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response N/A
Active, not recruiting NCT05748925 - Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT04517240 - A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
Completed NCT00710021 - Vitamin D3 in Systemic Lupus Erythematosus Phase 2
Terminated NCT01946880 - Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Phase 2
Recruiting NCT06445127 - Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) N/A
Active, not recruiting NCT04018222 - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed NCT03240536 - Choosing Tests Wisely in Rheumatology N/A
Completed NCT04368299 - Telemedicine for Follow-up of Systemic Lupus Erythematosus N/A
Active, not recruiting NCT04037293 - Premature Atherosclerosis in Systemic Lupus Erythematosus
Terminated NCT00152555 - Physical Therapy for Systemic Lupus Erythematosus (SLE) N/A
Completed NCT01207297 - Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Phase 1
Recruiting NCT05822219 - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases N/A
Completed NCT04806113 - COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases Phase 3
Recruiting NCT05966480 - Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus Phase 2
Completed NCT03155477 - Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D N/A
Recruiting NCT05342285 - Flow Mediated Dilation in Association With Hyperuricemia
Not yet recruiting NCT03984227 - New Signaling Pathway Targeting Systemic Lupus Erythematosus
Enrolling by invitation NCT03144063 - Improving the Assessment of SLE Disease Activity N/A